全文获取类型
收费全文 | 208篇 |
免费 | 4篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 2篇 |
妇产科学 | 5篇 |
基础医学 | 49篇 |
临床医学 | 30篇 |
内科学 | 43篇 |
神经病学 | 33篇 |
特种医学 | 5篇 |
外科学 | 12篇 |
一般理论 | 1篇 |
预防医学 | 3篇 |
眼科学 | 2篇 |
药学 | 9篇 |
中国医学 | 2篇 |
肿瘤学 | 16篇 |
出版年
2023年 | 2篇 |
2022年 | 4篇 |
2021年 | 15篇 |
2020年 | 10篇 |
2019年 | 5篇 |
2018年 | 4篇 |
2017年 | 4篇 |
2016年 | 3篇 |
2015年 | 4篇 |
2014年 | 10篇 |
2013年 | 15篇 |
2012年 | 15篇 |
2011年 | 16篇 |
2010年 | 9篇 |
2009年 | 10篇 |
2008年 | 7篇 |
2007年 | 9篇 |
2006年 | 16篇 |
2005年 | 12篇 |
2004年 | 9篇 |
2003年 | 9篇 |
2002年 | 5篇 |
2001年 | 2篇 |
2000年 | 2篇 |
1999年 | 1篇 |
1998年 | 1篇 |
1997年 | 1篇 |
1996年 | 2篇 |
1995年 | 2篇 |
1994年 | 1篇 |
1993年 | 1篇 |
1992年 | 1篇 |
1991年 | 1篇 |
1990年 | 2篇 |
1989年 | 4篇 |
1987年 | 1篇 |
排序方式: 共有215条查询结果,搜索用时 15 毫秒
21.
22.
Tissue inhibitor of metalloprotease (TIMP)‐1 and proliferative behaviour of clonal breast cancer cells 总被引:7,自引:0,他引:7
Claudio Luparello Grazia Avanzato Cintia Carella Ida Pucci‐Minafra 《Breast cancer research and treatment》1999,54(3):235-244
In the present paper, we have examined whether human tissue inhibitor of metalloprotease1 (hTIMP1) is able to exert a growth factorlike effect on two clonal cell lines (BC3A and BC61), isolated from a parental line of human breast carcinoma cells (8701BC), and endowed with different growth and invasive behaviour in vitro and in nude mouse. The data obtained indicate that only the more tumorigenic clonal cell line (BC61) is responsive to hTIMP1 treatment by increasing its proliferative rate in a dosedependent manner. It was also found that BC61 cells selectively express a transmembrane protein of about 80kDa able to bind hTIMP1 in vitro and in vivo with high affinity (Kd of 0.07 ± 0.004 nM), and that treatment of BC61 cells with a proliferationpromoting concentration of hTIMP1 is able to stimulate tyrosinetargeted phosphorylation. The cumulative results obtained strongly support the hypothesis that hTIMP1, classically regarded as a collagenase inhibitor, may be a crucial element of the extracellular signalling network during breast cancer development by controlling cell growth phenotype in autocrine and paracrine manner, and that intratumoural heterogeneity for the biological response to TIMP1 may exist within the composite cell population of the primary tumour site. 相似文献
23.
24.
Bartolini M Giamberardino MA Lisotto C Martelletti P Moscato D Panascia B Savi L Pini LA Sances G Santoro P Zanchin G Omboni S Ferrari MD Fierro B Brighina F 《The journal of headache and pain》2012,13(5):401-406
The objective of the study was to compare the efficacy and safety of frovatriptan and almotriptan in women with menstrually related migraine (IHS Classification of Headache disorders) enrolled in a multicenter, randomized, double-blind, cross-over study. Patients received frovatriptan 2.5?mg or almotriptan 12.5?mg in a randomized sequence: after treating 3 episodes of migraine in no more than 3?months with the first treatment, the patient was switched to the other treatment. 67 of the 96 female patients of the intention-to-treat population of the main study had regular menstrual cycles and were thus included in this subgroup analysis. 77 migraine attacks classified as related to menses were treated with frovatriptan and 78 with almotriptan. Rate of pain relief at 2 and 4?h was 36 and 53?% for frovatriptan and 41 and 50?% for almotriptan (p?=?NS between treatments). Rate of pain free at 2 and 4?h was 19 and 47?% with frovatriptan and 29 and 54?% for almotriptan (p?=?NS). At 24?h, 62?% of frovatriptan-treated and 67?% of almotriptan-treated patients had pain relief, while 60 versus 67?% were pain free (p?=?NS). Recurrence at 24?h was significantly (p?0.05) lower with frovatriptan (8 vs. 21?% almotriptan). This was the case also at 48?h (9 vs. 24?%, p?0.05). Frovatriptan was as effective as almotriptan in the immediate treatment of menstrually related migraine attacks. However, it showed a more favorable sustained effect, as shown by a lower rate of migraine recurrence. 相似文献
25.
Erkin Musabaev Chris Estes Shakhlo Sadirova Shokhista Bakieva Krestina Brigida Rick Dunn Shyamasundaran Kottilil Poonam Mathur Ameer Abutaleb Kathryn Razavi-Shearer Tim Anstiss Bakhodir Yusupaliev Homie Razavi 《Liver international》2023,43(4):773-784
Background & Aims
Chronic infection with hepatitis B and C viruses (HBV & HCV) is a major contributor to liver disease and liver-related mortality in Uzbekistan. There is a need to demonstrate the feasibility of large-scale simplified testing and treatment to implement a national viral hepatitis elimination program.Methods
Thirteen polyclinics were utilized to screen, conduct follow-up biochemical measures and treat chronic HBV and HCV infection in the general adult population. Task shifting and motivational interviewing training allowed nurses to provide rapid screening and general practitioners (GPs) to treat individuals on-site. An electronic medical system tracked individuals through the cascade of care.Results
The use of rapid tests allowed for screening of 60 769 people for HCV and HBV over 6 months and permitted outdoor testing during the COVID-19 pandemic along with COVID testing. 13%–14% of individuals were lost to follow-up after the rapid test, and another 62%–66% failed to come in for their consultation. One stop testing and treatment did not result in a statistically increase in retention and lack of patient awareness of viral hepatitis was identified as a key factor. Despite training, there were large differences between GPs and patients initiating treatment.Conclusions
The current study demonstrated the feasibility of large-scale general population screening and task shifting in low- and middle-income countries. However, such programs need to be proceeded by awareness campaign to minimize loss to follow up. In addition, multiple trainings are needed for GPs to bolster their skills to talk to patients about treatment. 相似文献26.
S Favale F Minafra G Amodio M Tritto V Massari P Rizzon 《International journal of cardiology》1990,28(3):347-352
This study was performed to evaluate whether transoesophageal atrial pacing could also stop ventricular tachycardias with low rates and no haemodynamic impairment. Prior to resorting to ventricular endocardial pacing, seven male patients, aged between 15 and 73 years, were treated by transoesophageal atrial pacing for 10 spontaneous episodes of sustained ventricular tachycardia at rates between 105 and 160 beats per minute, without haemodynamic impairment. When atrial pacing did not allow ventricular capture, atropine sulphate was administered. Transoesophageal atrial pacing led to ventricular capture in seven episodes, which made overdriving possible, and blocked six episodes of ventricular tachycardia. In no case did transoesophageal atrial pacing lead to an acceleration of ventricular tachycardia or to degeneration into ventricular fibrillation. Transoesophageal atrial pacing can block low-rate sustained ventricular tachycardias (less than or equal to 150 beats per minute). For low-rate sustained ventricular tachycardias without haemodynamic impairment, transoesophageal atrial pacing can thus be used as the method of choice thanks to its good ratio of risk to efficiency. 相似文献
27.
Giovanni Cossu Alessandra Mereu Marcello Deriu Maurizio Melis Andrea Molari Giannina Melis Laura Minafra Tiziana Pisano Carlo Cianchetti Enzo Ortu Gianfranco Sau Isidoro Aiello Miriana Fresu Maria Giovanna Marrosu Paolo Contu 《Movement disorders》2006,21(11):2005-2008
We performed a service-based epidemiological study of primary blepharospasm in the island of Sardinia (Italy). Due to its favorable geographical location, we are confident we will provide reliable data from patients seeking botulinum toxin treatment. A total of 53 patients were assessed. Prevalence was estimated to be 32.2 per 1 million (95% confidence interval, 23.0-40.8). These results are in line with those obtained in other similar surveys, that is, record-based, and performed in various European regions such as Northern England, the Munich area, as well as the Epidemiologic Study of Dystonia in Europe. 相似文献
28.
29.
30.
Matic S Minafra A Boscia D da Cunha AT Martelli GP 《Journal of virological methods》2009,155(1):72-76
Little cherry, an economically important disease of cherry is caused by at least two different viruses. One of these is Little cherry virus 1 (LChV-1) for the detection of which no efficient serological tools are available, so that diagnosis is based on molecular methods. In this study, different immunization strategies for producing antibodies against the viral coat protein of LChV-1 were tried, using either purified virus preparations, or bacterially expressed protein, or a DNA vector that expressed the cloned coat protein (CP) gene in vivo. Effective induction of specific antibodies to LChV-1 CP was obtained using DNA intramuscular immunization followed by a single boost with the recombinant protein. The entire coat protein sequence was cloned in a mammalian expression vector and, after being coated by an amphiphilic non-toxic reagent was delivered into rabbit. A protein boost increased the specific immune response against the virus protein. The sensitivity of this antiserum is lower if compared with that of antisera raised conventionally against other viruses, thus it requires improvements for use for diagnostic purposes. 相似文献